Ovulation induction with pulsatile luteinizing hormone-releasing hormone in women with clomiphene citrate-resistant polycystic ovary-like disease: endocrine results

Fertil Steril. 1989 Jan;51(1):20-9. doi: 10.1016/s0015-0282(16)60422-3.

Abstract

The pituitary and gonadal response to pulsatile luteinizing hormone-releasing hormone (LH-RH) administration during the first and consecutive second treatment unit (TU) was studied in nine women with clomiphene citrate-resistant polycystic ovary-like disease (PCOD). The control group consisted of eight eumenorrheic women. Luteinizing hormone levels, LH amplitudes, and total urinary excretion/24 hours did not differ between ovulatory and anovulatory TUs, but were significantly higher compared with the control group. Follicle-stimulating hormone (FSH) in PCOD did not differ from normal cycles. Androgen values in the anovulatory TUs were significantly higher compared with the ovulatory TUs (P = 0.001). We conclude that LH-RH therapy may result in ovulation; however, it does not redress the intrinsic abnormality in PCOD and FSH, and androgen levels do not seem to be critical in ovulation induction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Androstenedione / blood
  • Clomiphene / therapeutic use
  • Estrogens / urine
  • Female
  • Follicle Stimulating Hormone / blood
  • Gonadotropin-Releasing Hormone / administration & dosage*
  • Humans
  • Luteinizing Hormone / blood
  • Ovulation Induction / methods*
  • Polycystic Ovary Syndrome / drug therapy
  • Polycystic Ovary Syndrome / metabolism
  • Polycystic Ovary Syndrome / therapy*
  • Testosterone / blood

Substances

  • Estrogens
  • Clomiphene
  • Gonadotropin-Releasing Hormone
  • Testosterone
  • Androstenedione
  • Luteinizing Hormone
  • Follicle Stimulating Hormone